Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study reveals dynamic nature of myelin swellings

12

Feb 2026

Study reveals dynamic nature of myelin swellings

An international research team of Amsterdam UMC, VU LaserLab, the Netherlands Institute for Neuroscience and the University of Edinburgh have gained new insights into the dynamics of myelin swellings in the brain.

Abortion restrictions linked to higher maternal death rates

12

Feb 2026

Abortion restrictions linked to higher maternal death rates

​The increased number of state-level abortion restrictions in the U.S. was associated with a parallel increase in maternal deaths between 2005 and 2023, according to new research presented today at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting.

Academic pressure at age 15 linked to depression

12

Feb 2026

Academic pressure at age 15 linked to depression

Pressure to achieve at school at age 15 is linked to depressive symptoms and risk of self-harm, and the association appears to persist into adulthood, finds a study led by University College London (UCL) researchers.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.